Bevacizumab对大鼠角膜新生血管抑制及其超微结构影响的实验研究
|
摘要
目的:探讨贝伐单抗对角膜新生血管形成及角膜内血管内皮生长因子(VEGF)的影响及其超微结构的影响。
方法:盘实验用Wistar大鼠128只随机分4组,采有碱烧伤的方法制备大鼠角膜新生血管模型。正常不烧伤组32只,1、烧伤后隔日球结膜下注射0.1毫升生理盐水组(32只),2、烧伤后隔日球结膜下注射贝伐单抗0.1毫升组(32只),3、烧伤后隔日球结膜下注射地塞米松0.1毫升组(32只)。碱烧伤术后在裂隙灯显微镜下观察大鼠角膜混浊度；宏观测量新生血管长度：组织病理切片HE染色作微血管计数；透射电镜观察超微结构的改变；免疫组化检测角膜VEGF的蛋白表达情况；CD34标记新生血管,显微镜下微血管计数方法研究角膜新生血管形成及抑制情况。
结果:治疗组在3、7、10、14天较对照组角膜混浊程度轻(P<0.05)；第14天形成的新生血管数量较对照组少(P<0.05)实验组新生血管微血管数量减少,VEGF蛋白表达下降,具有统计学差异。VEGF主要表达在角膜受损区的感染细胞胞浆内,其出现时间与位置与角膜新生血管一致。贝伐单抗和地塞米松均可有效抑制角膜新生血管,减少角膜内VEGF表达,两者无统计学差异,结膜下注射贝伐单抗和地塞米松后,大鼠角膜超微结构无除烧伤后其它显著改变。
结论：VEGF是一种重要的角膜内新生血管形成因子,其变化与角膜新生血管平行;一定剂量贝伐单抗、地塞米松可抑制角膜新生血管,减少角膜内VEGF表达,且两者对角膜的超微结构均无显著药物毒性。。
AIM:To explore the Bevacizumab therapy for neovascularization of the rat cornea and its impact on the ultrastructure
M ethods:established,Wistar rats were selected for four groups at random, Group1 (n=32) normal; Group2 (n=32) received a subconjunctival injection of 0.1ml of 0,9% saline solution; Group3 (n=32) received a subconjunctival injection of 0.1 ml bevacizumab group; Group4 (n=32) received a subconjunctival injection of 0.1 ml dexamethasone group。All groups were observed the corneal opacity by slit-lamp microscope at day,3,7,10,14 after corneal alkali burns.neovascularization were evaluated histological after enucleation,fixation with formaldehyde solution,and staining with hematoxylin and eosin(HE).The contents of blood vessel in corneas were measured.Corneal ultrastructural morphology was observed by transmission electron microscope(TEM).The localization and expression of VEGF,CD34 were determined by immunohistochemical method.
Result:lt was found that corneal opacity was slighter in treatment group than that in control group at day 3,7,10,14 after cautery,which there were statistically significant difference between the treatment group and the control group (P<0.05).From the point of neovascularization counted number,the rat corneal neovascularization in the treatment group was less than that in the control group at day 14 after alkali burn (P<0.05).3,7,10,14,with statistically significant difference (P<0.05).The expressions of VEGF,CD34 in normal rat's cornea were restricted in epithelia and endothelial cell,and VEGF increased gradually at day 3,subsequently the expression decreased slowly after this.There was no difference among bevacizumab and dexamethasone.
Conclusion:Bevacizumab can effectively restrain corneal neovascularization and reduce the corneal opacity. VEGF play important parts in alkali burn of the rat cornea. Bevacizumab therapy may ameliorate corneal alkali burn by effecting with those factors. Bevacizumab therapy for alkali burn is safe andutility.
方法:盘实验用Wistar大鼠128只随机分4组,采有碱烧伤的方法制备大鼠角膜新生血管模型。正常不烧伤组32只,1、烧伤后隔日球结膜下注射0.1毫升生理盐水组(32只),2、烧伤后隔日球结膜下注射贝伐单抗0.1毫升组(32只),3、烧伤后隔日球结膜下注射地塞米松0.1毫升组(32只)。碱烧伤术后在裂隙灯显微镜下观察大鼠角膜混浊度；宏观测量新生血管长度：组织病理切片HE染色作微血管计数；透射电镜观察超微结构的改变；免疫组化检测角膜VEGF的蛋白表达情况；CD34标记新生血管,显微镜下微血管计数方法研究角膜新生血管形成及抑制情况。
结果:治疗组在3、7、10、14天较对照组角膜混浊程度轻(P<0.05)；第14天形成的新生血管数量较对照组少(P<0.05)实验组新生血管微血管数量减少,VEGF蛋白表达下降,具有统计学差异。VEGF主要表达在角膜受损区的感染细胞胞浆内,其出现时间与位置与角膜新生血管一致。贝伐单抗和地塞米松均可有效抑制角膜新生血管,减少角膜内VEGF表达,两者无统计学差异,结膜下注射贝伐单抗和地塞米松后,大鼠角膜超微结构无除烧伤后其它显著改变。
结论：VEGF是一种重要的角膜内新生血管形成因子,其变化与角膜新生血管平行;一定剂量贝伐单抗、地塞米松可抑制角膜新生血管,减少角膜内VEGF表达,且两者对角膜的超微结构均无显著药物毒性。。
AIM:To explore the Bevacizumab therapy for neovascularization of the rat cornea and its impact on the ultrastructure
M ethods:established,Wistar rats were selected for four groups at random, Group1 (n=32) normal; Group2 (n=32) received a subconjunctival injection of 0.1ml of 0,9% saline solution; Group3 (n=32) received a subconjunctival injection of 0.1 ml bevacizumab group; Group4 (n=32) received a subconjunctival injection of 0.1 ml dexamethasone group。All groups were observed the corneal opacity by slit-lamp microscope at day,3,7,10,14 after corneal alkali burns.neovascularization were evaluated histological after enucleation,fixation with formaldehyde solution,and staining with hematoxylin and eosin(HE).The contents of blood vessel in corneas were measured.Corneal ultrastructural morphology was observed by transmission electron microscope(TEM).The localization and expression of VEGF,CD34 were determined by immunohistochemical method.
Result:lt was found that corneal opacity was slighter in treatment group than that in control group at day 3,7,10,14 after cautery,which there were statistically significant difference between the treatment group and the control group (P<0.05).From the point of neovascularization counted number,the rat corneal neovascularization in the treatment group was less than that in the control group at day 14 after alkali burn (P<0.05).3,7,10,14,with statistically significant difference (P<0.05).The expressions of VEGF,CD34 in normal rat's cornea were restricted in epithelia and endothelial cell,and VEGF increased gradually at day 3,subsequently the expression decreased slowly after this.There was no difference among bevacizumab and dexamethasone.
Conclusion:Bevacizumab can effectively restrain corneal neovascularization and reduce the corneal opacity. VEGF play important parts in alkali burn of the rat cornea. Bevacizumab therapy may ameliorate corneal alkali burn by effecting with those factors. Bevacizumab therapy for alkali burn is safe andutility.
引文
[1]Williams KA,Muhelberg SM,Lewis RF,et al.How successful is corneal transplantation?A report from the Australian Corneal Graft Register.Eye,1995,9(2):219-227.
[2]Ycao.Endogenous,angiogenesis inhibitors and their therapeutic implications.Internet J Biochem & Cell Biol,2001,33(4):357-369.
[3]Streilein JW,Bradley D,Sano Y,et al.Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas.Invest Ophthalmol Vis Sci,1996,3V(2):413-424.
[4]Dana MR and Streilein JW.Loss and restoration of immune privilege in eyes with corneal neovascularization.Invest Ophthalmol Vis Sci,1996,37(12):2485-2494.
[5]Sloper CM,Powell RJ and Dua HS.Tacrolimus(FK506)in the management of high-risk corneal and limbal grafts.Ophthalmology,2001,108(10):1838-1844.
[6]Yamada J,Dana MR.Local suppression of IL-1 by receptor antagorust in the rat mode pf corneal alkali injury.Exp Eye Rea.2003,76;161-167.
[7]D Amato RJ,Loushnail MS,Flypn E,et al.Thalldomide is aninhibitor of an giogenesis.Proc Ncad Sci USA,1994,91:4082-4085.
[8]颜世龙,梁丹.碱烧伤大鼠角膜新生血管模型的初步探索.眼科学报,2005,21(4)：165-172.
[9]Zhang H,Li C,Baciu PC.ExPression of integrins and MMPs during alkaline-burn-induced comeal angiogenesis.Invest Ophthalmol Vis Sci,2002,43(4):955-962.
[10]MeyerM,ClauasM,Lepple-W ienhues AL.A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E mediates angiogenesis via signaling through VEGFR-(KDR) but not VEGFR-1(Flt-1) receptor tyrosine kinas[J].EMBO J1999;18(2):363-374.
[11]Neufeld G,Cohen T,Gengrinovitch S, Poltorak Z.Vascular endothelial growth factor (VEGF) and its receptors[J]FASEB J1999; 13(1):9-22.
[12]BhisitkulRB. Vascular endothelial growth factor biology clinical implications for ocular treatments[J].Br J Ophthalmol 2006;90:1542-1547.
[13]CrossMJ,Claeason-Welah I.FGF and VEGF function in angiogenesis:signaling pathways, biological responses an therapeutic inhibition [J]. Trends Pharmacol Sci2001;2(4):201-207.
[14]Seghezzi G,Patel S,Ren CJ,et al.Fibroblast growth factor-2(FGF-2)induces vascular endothelial growth factor(VEGF)expression in the endothelial cells of forming c
[15]de Vries C,Escobedo JA,UenoH,HouckK,Ferrara N,W iliam s LT.The fm s-like tyrosine kinase, a receptor for vascular endothelial growth factor[J].Sciencel992;255:989-991.
[16]apillaries:an autocrine mechanism contributing to angiogenesis.J Cell Biol,1998,141:1659-1673.
[17]Dvorak HF,Brown LF,Detmar,et al.Vascular permeability factor/vascular endothelial growth factor,microvascular hypenneability,and angiogenesis.Am J Pathol,1995,146(5):1029-1039.
[18]Breier G,Albrechet D,Sterrer S,et al.Expression of vascuar endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation.Development,1992,114(2):521-532.
[19]Severinghaus JW.Hypothetical roles of angiogenesis,osmotic swelling,and ischemia in high-altitude cerebral edema.J Appl Physiol,1995,79(2):375-379.
[20]陈嘉宁,黄巧玲,姜文浩.血管内皮生长因子在碱烧伤角膜新生血管中表达的研究.中国老年学杂志.2005,25：1006-1008.
[21]杨艳,张明吕.人参皂甙Rg3在大鼠角膜新生血管中的作用研究.眼科研究.2007,25(8)：580-583.
[22]程蕾,张明昌.非洛贝特对大鼠角膜新生血管的影响.眼视光学杂志.2007,9(2)：83-86.
[23]杨艳,张明昌,张波.血管内皮生长因子及其受体在大鼠碱烧伤后角膜新生血管中的表达.国际眼科杂志.2006,6(6)：1320-1322.
[24]HurwitzH, FehrenbacherL, NovotnyW, etal. Bevacizumab plus irinotecan, fluorouracil and leucovorin formetastatic colorectalcancer. NEngl JMed2004;350(23):2335-2342
[25]朱洁,王雨生,惠延年.脉络膜新生血管的生成和抑制.眼科新进展2004；24：57-60
[26]高峨嵋,徐建明VEGF靶向药Avastin治疗实体瘤的研究进展[J].中国肿瘤临床与康复2006；13(5)：473-475.
[27]Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC,Lowman HB,et al. VEGF and the Fab fragment of a humanized neutralizing antibody:crystal structure of the complex at2.4A resolution and mutational analysis of the interface[J].Structure1998;6(9):1153-1167.
[28]Fernando NH,HurwitzHI. Inhibition of vascular endothelial growth factor in the treatmentofcolorectalcancer[J].Sem in Oncol2003;30(3):39-50.
[29]ErdurmusM,TotanY. Subconjunctival avastin for corneal neovascularization. GraefeArch Clin ExpOphthalmoI2007;26(5):1125-1129
[30]IlievME, DomigD, Wolf-SchnurrburschU, etal. Intravitreal bevacizumab(Avastin) in the treatment of neovascular glaucoma. Am JOphthaml ol2006; 142:1054-1056
[31]DavidorfFH, Mouser JG, Derick RJ. Rapid mi provement of rubeosis iridis from a single bevacizumab(avastin) injection. Retina2006;26(3):354-356
[32]Yoeruek E, SpitzerMS, TatarO, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea2007;26(8):977-982
[33]BenelliR, MoriniM, CarrozzinoF, etal. Neutrophilsasa key cellular target for angiostatin:mi plications for regulation of angiogenesis and in-flammation. Faseb J2002;16(2):267-269
[34]HamidHossein,i MohammadRezaKhalil.i Therapeutic potential of bevacizumab(Avastin) in herpetic stromal keratitis (HSK). MedicalHypotheses2007;69:568-570
[35]ManzanoRPA, PeymanGA, Khan P, etal. Inhibition ofexpermi ental cornealneovascularisation by bevacizumab (Avastin). Br JOphthalmol2007;91:804-807
[36]Destafeno JJ, Kmi T.Topicalbevacizumab therapy for corneal neovascularization. ArchOphthalmol2007;125(6):834-836
[1]Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J. Unbalanced expression of VEGFand PEDF in ischemia-induced retinal neovascularization. FEBS Lett,2001;489(2-3):270-276
[2]Gao G, Ma J. Tipping the balance for angiogenic disorders. Drug Discov Today,2002;7(3):171-172
[3]Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, Cassatella M,NoonanDM,AlbiniA.Neutrophils as a keycellular target for angiostatin:implications for regulation of angiogenesis and inflammation. Faseb J,2002;16(2):267-269
[4]易伟华,魏锐利,蔡季平,李玉莉.血管内皮生长因子和转化生长因子β1在眼眶海绵状血管瘤的表达及意义.国际眼科杂志,2004；4(4)：247-249
[5]Presta LG,Chen H,O'Connor SJ, Chisholm V,Meng YG,Krummen L,et al.Humanization of an anti-vascular endo-thelial growth factormonoclonal antibody for the therapy of solid tumors and other disorders [J].CancerRes1997;57(20):4593-4599
[6]Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, Kinoshita S. Growth factors:importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res,2000;19(1):113-129
[7]Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci,2000;41(9):2514-2522
[8]王启常,唐罗生.外源性VEGF诱导的大鼠视网膜血管病变.国际眼科杂志,2006；6(2)：369-372
[9]Wang F, Rendahl KG, Manning WC, Quiroz D, Coyne M, Miller SS.AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest Ophthalmol Vis Sci,2003;44(2):781-790
[10]BaknsJ, SnyderM R, nllidoJS, etla. Six-month stabilityofbey-Avastin bniding to vascular endothelial growth factor after withdrawla into a syringe and refrigeration or freezing. Retina,2006.26: 519-522.
[11]JainRK.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy [J].Science2005;307:58-62.
[12]Hofman P, van Blijswijk BC,Gaillard PJ,Vrensen GF, Schlingemann RO. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina-new insights into the pathogenesis ofcapillary nonperfusion[J].Arch Ophthalm ol2001;119:861-866.
[13]Tolentino M J, Miller J W,GragoudasES,Chatzistefanou K, Ferrara N, Adam is AP. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate[J].Arch Ophthalmol 1996; 114:964-970.
[14]Adam is AP, Shima DT, Tolentino MJ,Gragoudas ES, Ferrara N,Folkman J,et al. Inhibition of vascular endothelial growth factor prevents retina lischemia-associated iris neovascularization in a nonhuman primate[J].Arch Ophthalmol 1996; 114:66-71.
[15]Adam is AP,M iller JW, BernalMT,D'Am ico DJ, Folkman J,Yeo TK,et al. Increased VEGF levels in the vitreous of eyes with proliferative diabetic retinopathy[J].Am J Ophthalmol 1994;118:445-450.
[16]16Ogata N,Nishikawa M, Nishimura T, MitsumaY,Matsumura M. Unbalanced vitreous pigment epithelium-derived factor and levels of vascular endothelial growth factor indiabetic retinopathy [J].Am J Ophthalmol2002;134:348-353.
[17]Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T,Hori S. Increased levels of vascular endothelial growth factor and interleukin-6in the aqueous humor ofdiabetics with macular edema [J].Am J Ophthalmol2002;133:70-77.
[18]Lip PL,Blann AD,Hope-RossM,Gibson JM, Lip GY. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction [J].Ophthalmology2001;108:705-710.
[19]Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of interleukin-6[J].Am J Ophthalmol2005;140:256-257.
[20]Luthra S, Narayanan R, Marques LE, et al. Evaluation of invitro Effecst of bevaeizumab(Avastin) on retinal pigment epithelial, neu-Rosensory retinal, and micro vascular endothelila cells. Retina, 200626:512-518.
[21]KemtM, NeubanerAS, KampikA. Intraivtreal bevaezumab(Avastin)treatment is safe in tenrm of nitmcoular and blood pressure. Acat Ophthalmol Scand,2007,85:119-120.
[22]KissC, MiehelsS, PragerF, etla. Evaluation of anterior chamber Inflammatory activity in eyes treated with intravitreal bevacizumab. Retina,2006,26:877-881.
[23]LucasRS, M Kee}ml R, LeeU, etal. Intravitreal bevaciznumb. Ophthalmology,2007,114:400.
[24]Roberta P A Manzano, Gholam A Peyman, Palwasha Khan, Petros E Carvounis, Muhamet Kivilcim,Min Ren, Jonathan C Lake, Patricia Che'vez-Barrios Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin) Br J Ophthalmol 2007;91:804-807. doi: 10.1136/bjo.2006.107912
[25]Luiz F.M. Barrosi and Rubens Belfort The effects of the subconjunctival injection of bevacizumab (Avastin_) on angiogenesis in the rat cornea An Acad Bras Cienc (2007) 79 (3)
[26]Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence omography findings after all intravitreal injection of bevacizumab(avastin) for neovasoular age-related macular degeneration J. Ophthalmol Surgtserhnag,2005,36(4):331-335.
[27]Laud K, Spaide RF, Freund KB, et al. Treatment of ehoroidal neovascularization in patholagic myopia with intravitreal bevacizumab[J]. Retina,2006,26(8):960-963.
[28]Sohman W, Laud A, Larsen M. Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal nevascularization 1 J]. Acta Ophthalmol Seand, 2006.84(5):707.708.
[29]Teixeira A, Moraesn, Farah me, et al. Choroidan Eovascularization treated with intravitreal injection of bevacizumab(avastin)in angioid streaks[J]. Acta Ophthalmol Stand,2006,84(6): 835.836.
[30]Spaide RF, Fisher YL. Intravitreal bevaeizumab(avastin)treatment of proliferative diabetic retinopathy complicated by vitreous hemon'hage J. Retina.2006,26(3):275.278
[31]Siqueika RC, Costa RA, Scott IU, et al. Intravitreal txevacizumab(avastin)injection associated with regression of retinal neovascularization cansed by sickle cell retinopathy[J]. Acta Ophthalmol Seand, 2006,84(6):834-835.
[32]Shah PK, Narendran V, Tawansy KA, et al. Intravitreal bevacizumab(avastin) for pest laser anterior segment ischemia in aggressive posterior retinopathy of prematurity[J]. Indian J Ophthalmol,2007, 55(1):75.76.
[33]Bomaggio F, Eidfarah M, Meid GB. Intravitreal bevacizumab for occult ehoroidal neovascularization with pigment epithelium detachment in age-related lnaculal"degeneration[J]. Acta Ophthmol Scmld, 2006,84(5):713-714.
[34]Mason JO, Albert ma JR, Vail R. Intravitreal bevacizumab (avastin)for refractou pseudOphakic eystoid macular edema [J]. Retina,2006,26(3):356-357.
[2]Ycao.Endogenous,angiogenesis inhibitors and their therapeutic implications.Internet J Biochem & Cell Biol,2001,33(4):357-369.
[3]Streilein JW,Bradley D,Sano Y,et al.Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas.Invest Ophthalmol Vis Sci,1996,3V(2):413-424.
[4]Dana MR and Streilein JW.Loss and restoration of immune privilege in eyes with corneal neovascularization.Invest Ophthalmol Vis Sci,1996,37(12):2485-2494.
[5]Sloper CM,Powell RJ and Dua HS.Tacrolimus(FK506)in the management of high-risk corneal and limbal grafts.Ophthalmology,2001,108(10):1838-1844.
[6]Yamada J,Dana MR.Local suppression of IL-1 by receptor antagorust in the rat mode pf corneal alkali injury.Exp Eye Rea.2003,76;161-167.
[7]D Amato RJ,Loushnail MS,Flypn E,et al.Thalldomide is aninhibitor of an giogenesis.Proc Ncad Sci USA,1994,91:4082-4085.
[8]颜世龙,梁丹.碱烧伤大鼠角膜新生血管模型的初步探索.眼科学报,2005,21(4)：165-172.
[9]Zhang H,Li C,Baciu PC.ExPression of integrins and MMPs during alkaline-burn-induced comeal angiogenesis.Invest Ophthalmol Vis Sci,2002,43(4):955-962.
[10]MeyerM,ClauasM,Lepple-W ienhues AL.A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E mediates angiogenesis via signaling through VEGFR-(KDR) but not VEGFR-1(Flt-1) receptor tyrosine kinas[J].EMBO J1999;18(2):363-374.
[11]Neufeld G,Cohen T,Gengrinovitch S, Poltorak Z.Vascular endothelial growth factor (VEGF) and its receptors[J]FASEB J1999; 13(1):9-22.
[12]BhisitkulRB. Vascular endothelial growth factor biology clinical implications for ocular treatments[J].Br J Ophthalmol 2006;90:1542-1547.
[13]CrossMJ,Claeason-Welah I.FGF and VEGF function in angiogenesis:signaling pathways, biological responses an therapeutic inhibition [J]. Trends Pharmacol Sci2001;2(4):201-207.
[14]Seghezzi G,Patel S,Ren CJ,et al.Fibroblast growth factor-2(FGF-2)induces vascular endothelial growth factor(VEGF)expression in the endothelial cells of forming c
[15]de Vries C,Escobedo JA,UenoH,HouckK,Ferrara N,W iliam s LT.The fm s-like tyrosine kinase, a receptor for vascular endothelial growth factor[J].Sciencel992;255:989-991.
[16]apillaries:an autocrine mechanism contributing to angiogenesis.J Cell Biol,1998,141:1659-1673.
[17]Dvorak HF,Brown LF,Detmar,et al.Vascular permeability factor/vascular endothelial growth factor,microvascular hypenneability,and angiogenesis.Am J Pathol,1995,146(5):1029-1039.
[18]Breier G,Albrechet D,Sterrer S,et al.Expression of vascuar endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation.Development,1992,114(2):521-532.
[19]Severinghaus JW.Hypothetical roles of angiogenesis,osmotic swelling,and ischemia in high-altitude cerebral edema.J Appl Physiol,1995,79(2):375-379.
[20]陈嘉宁,黄巧玲,姜文浩.血管内皮生长因子在碱烧伤角膜新生血管中表达的研究.中国老年学杂志.2005,25：1006-1008.
[21]杨艳,张明吕.人参皂甙Rg3在大鼠角膜新生血管中的作用研究.眼科研究.2007,25(8)：580-583.
[22]程蕾,张明昌.非洛贝特对大鼠角膜新生血管的影响.眼视光学杂志.2007,9(2)：83-86.
[23]杨艳,张明昌,张波.血管内皮生长因子及其受体在大鼠碱烧伤后角膜新生血管中的表达.国际眼科杂志.2006,6(6)：1320-1322.
[24]HurwitzH, FehrenbacherL, NovotnyW, etal. Bevacizumab plus irinotecan, fluorouracil and leucovorin formetastatic colorectalcancer. NEngl JMed2004;350(23):2335-2342
[25]朱洁,王雨生,惠延年.脉络膜新生血管的生成和抑制.眼科新进展2004；24：57-60
[26]高峨嵋,徐建明VEGF靶向药Avastin治疗实体瘤的研究进展[J].中国肿瘤临床与康复2006；13(5)：473-475.
[27]Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC,Lowman HB,et al. VEGF and the Fab fragment of a humanized neutralizing antibody:crystal structure of the complex at2.4A resolution and mutational analysis of the interface[J].Structure1998;6(9):1153-1167.
[28]Fernando NH,HurwitzHI. Inhibition of vascular endothelial growth factor in the treatmentofcolorectalcancer[J].Sem in Oncol2003;30(3):39-50.
[29]ErdurmusM,TotanY. Subconjunctival avastin for corneal neovascularization. GraefeArch Clin ExpOphthalmoI2007;26(5):1125-1129
[30]IlievME, DomigD, Wolf-SchnurrburschU, etal. Intravitreal bevacizumab(Avastin) in the treatment of neovascular glaucoma. Am JOphthaml ol2006; 142:1054-1056
[31]DavidorfFH, Mouser JG, Derick RJ. Rapid mi provement of rubeosis iridis from a single bevacizumab(avastin) injection. Retina2006;26(3):354-356
[32]Yoeruek E, SpitzerMS, TatarO, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea2007;26(8):977-982
[33]BenelliR, MoriniM, CarrozzinoF, etal. Neutrophilsasa key cellular target for angiostatin:mi plications for regulation of angiogenesis and in-flammation. Faseb J2002;16(2):267-269
[34]HamidHossein,i MohammadRezaKhalil.i Therapeutic potential of bevacizumab(Avastin) in herpetic stromal keratitis (HSK). MedicalHypotheses2007;69:568-570
[35]ManzanoRPA, PeymanGA, Khan P, etal. Inhibition ofexpermi ental cornealneovascularisation by bevacizumab (Avastin). Br JOphthalmol2007;91:804-807
[36]Destafeno JJ, Kmi T.Topicalbevacizumab therapy for corneal neovascularization. ArchOphthalmol2007;125(6):834-836
[1]Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J. Unbalanced expression of VEGFand PEDF in ischemia-induced retinal neovascularization. FEBS Lett,2001;489(2-3):270-276
[2]Gao G, Ma J. Tipping the balance for angiogenic disorders. Drug Discov Today,2002;7(3):171-172
[3]Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, Cassatella M,NoonanDM,AlbiniA.Neutrophils as a keycellular target for angiostatin:implications for regulation of angiogenesis and inflammation. Faseb J,2002;16(2):267-269
[4]易伟华,魏锐利,蔡季平,李玉莉.血管内皮生长因子和转化生长因子β1在眼眶海绵状血管瘤的表达及意义.国际眼科杂志,2004；4(4)：247-249
[5]Presta LG,Chen H,O'Connor SJ, Chisholm V,Meng YG,Krummen L,et al.Humanization of an anti-vascular endo-thelial growth factormonoclonal antibody for the therapy of solid tumors and other disorders [J].CancerRes1997;57(20):4593-4599
[6]Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, Kinoshita S. Growth factors:importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res,2000;19(1):113-129
[7]Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci,2000;41(9):2514-2522
[8]王启常,唐罗生.外源性VEGF诱导的大鼠视网膜血管病变.国际眼科杂志,2006；6(2)：369-372
[9]Wang F, Rendahl KG, Manning WC, Quiroz D, Coyne M, Miller SS.AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest Ophthalmol Vis Sci,2003;44(2):781-790
[10]BaknsJ, SnyderM R, nllidoJS, etla. Six-month stabilityofbey-Avastin bniding to vascular endothelial growth factor after withdrawla into a syringe and refrigeration or freezing. Retina,2006.26: 519-522.
[11]JainRK.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy [J].Science2005;307:58-62.
[12]Hofman P, van Blijswijk BC,Gaillard PJ,Vrensen GF, Schlingemann RO. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina-new insights into the pathogenesis ofcapillary nonperfusion[J].Arch Ophthalm ol2001;119:861-866.
[13]Tolentino M J, Miller J W,GragoudasES,Chatzistefanou K, Ferrara N, Adam is AP. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate[J].Arch Ophthalmol 1996; 114:964-970.
[14]Adam is AP, Shima DT, Tolentino MJ,Gragoudas ES, Ferrara N,Folkman J,et al. Inhibition of vascular endothelial growth factor prevents retina lischemia-associated iris neovascularization in a nonhuman primate[J].Arch Ophthalmol 1996; 114:66-71.
[15]Adam is AP,M iller JW, BernalMT,D'Am ico DJ, Folkman J,Yeo TK,et al. Increased VEGF levels in the vitreous of eyes with proliferative diabetic retinopathy[J].Am J Ophthalmol 1994;118:445-450.
[16]16Ogata N,Nishikawa M, Nishimura T, MitsumaY,Matsumura M. Unbalanced vitreous pigment epithelium-derived factor and levels of vascular endothelial growth factor indiabetic retinopathy [J].Am J Ophthalmol2002;134:348-353.
[17]Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T,Hori S. Increased levels of vascular endothelial growth factor and interleukin-6in the aqueous humor ofdiabetics with macular edema [J].Am J Ophthalmol2002;133:70-77.
[18]Lip PL,Blann AD,Hope-RossM,Gibson JM, Lip GY. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction [J].Ophthalmology2001;108:705-710.
[19]Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of interleukin-6[J].Am J Ophthalmol2005;140:256-257.
[20]Luthra S, Narayanan R, Marques LE, et al. Evaluation of invitro Effecst of bevaeizumab(Avastin) on retinal pigment epithelial, neu-Rosensory retinal, and micro vascular endothelila cells. Retina, 200626:512-518.
[21]KemtM, NeubanerAS, KampikA. Intraivtreal bevaezumab(Avastin)treatment is safe in tenrm of nitmcoular and blood pressure. Acat Ophthalmol Scand,2007,85:119-120.
[22]KissC, MiehelsS, PragerF, etla. Evaluation of anterior chamber Inflammatory activity in eyes treated with intravitreal bevacizumab. Retina,2006,26:877-881.
[23]LucasRS, M Kee}ml R, LeeU, etal. Intravitreal bevaciznumb. Ophthalmology,2007,114:400.
[24]Roberta P A Manzano, Gholam A Peyman, Palwasha Khan, Petros E Carvounis, Muhamet Kivilcim,Min Ren, Jonathan C Lake, Patricia Che'vez-Barrios Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin) Br J Ophthalmol 2007;91:804-807. doi: 10.1136/bjo.2006.107912
[25]Luiz F.M. Barrosi and Rubens Belfort The effects of the subconjunctival injection of bevacizumab (Avastin_) on angiogenesis in the rat cornea An Acad Bras Cienc (2007) 79 (3)
[26]Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence omography findings after all intravitreal injection of bevacizumab(avastin) for neovasoular age-related macular degeneration J. Ophthalmol Surgtserhnag,2005,36(4):331-335.
[27]Laud K, Spaide RF, Freund KB, et al. Treatment of ehoroidal neovascularization in patholagic myopia with intravitreal bevacizumab[J]. Retina,2006,26(8):960-963.
[28]Sohman W, Laud A, Larsen M. Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal nevascularization 1 J]. Acta Ophthalmol Seand, 2006.84(5):707.708.
[29]Teixeira A, Moraesn, Farah me, et al. Choroidan Eovascularization treated with intravitreal injection of bevacizumab(avastin)in angioid streaks[J]. Acta Ophthalmol Stand,2006,84(6): 835.836.
[30]Spaide RF, Fisher YL. Intravitreal bevaeizumab(avastin)treatment of proliferative diabetic retinopathy complicated by vitreous hemon'hage J. Retina.2006,26(3):275.278
[31]Siqueika RC, Costa RA, Scott IU, et al. Intravitreal txevacizumab(avastin)injection associated with regression of retinal neovascularization cansed by sickle cell retinopathy[J]. Acta Ophthalmol Seand, 2006,84(6):834-835.
[32]Shah PK, Narendran V, Tawansy KA, et al. Intravitreal bevacizumab(avastin) for pest laser anterior segment ischemia in aggressive posterior retinopathy of prematurity[J]. Indian J Ophthalmol,2007, 55(1):75.76.
[33]Bomaggio F, Eidfarah M, Meid GB. Intravitreal bevacizumab for occult ehoroidal neovascularization with pigment epithelium detachment in age-related lnaculal"degeneration[J]. Acta Ophthmol Scmld, 2006,84(5):713-714.
[34]Mason JO, Albert ma JR, Vail R. Intravitreal bevacizumab (avastin)for refractou pseudOphakic eystoid macular edema [J]. Retina,2006,26(3):356-357.